EUCTR2007-002015-38-HU进行中（未招募）不适用
Phase II, multicenter, randomized, double-blind, intraindividually placebo controlled clinical trial, to evaluate efficacy and safety of P144 topical administration for skin fibrosis in patients with systemic sclerosis.Fázis II, multicentrikus, randomizált, kettos vak, egyénenként placebóval kontrollált klinikai vizsgálat, különbözo koncentrációjú topikus P144 hatékonyságának és biztonságosságának megállapítása szisztémás sclerosis-ban szenvedo páciensek bor fibrózisának kezelésében.
ISDI0 个研究点目标入组 98 人开始时间: 2007年7月9日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 98
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •·Patients male and female >18 < 65 years at time of consent.
- •·History of Systemic sclerosis (including diffuse scleroderma and limited scleroderma) for less than three years of evolution from the onset of cutaneous manifestations.
- •·Symmetric lesions in forearms. The extension of the selected symmetric lesions must be at least 15 cm2.
- •·Stable therapy for at least one month, except in the case of patients under treatment with putative disease modifying agents (immunosupressants like cyclophosphamide, methotrexate or azathioprine) that will need at least three months of stable therapy, without the expectation of treatment modifications during the trial period.
- •·Capable of understanding and willing to provide signed and dated written voluntary informed consent before any protocol specific procedures are performed.
- •·For female subjects with childbearing potential: use of a known highly effective method of birth control, defined as those which results in a low failure rate: i.e. less 1% per year, (contraceptive pills, intrauterine contraceptive device, implants, vasectomized partner or sexual abstinence), for at least three consecutive months prior to the study, during the study and one month after the end of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •·Patients diagnosed of:
- •oSystemic sclerosis sine scleroderma.
- •oLocalized scleroderma.
- •oEosinophilic fascitis, eosinophilia myalgia syndrome.
- •·Any other definable connective tissue disease, such as rheumatoid arthritis, systemic lupus erythematosus, polymyositis, or dermatomyositis.
- •·Clinically significant overlap condition.
- •·Significant existing internal organ damage (Kidney, Cardiovascular disease, Pulmonary disease, Gastrointestinal disease) as defined in Guidelines for clinical trial in systemic sclerosis (scleroderma)
- •·History of skin cancer.
- •·Other skin diseases affecting the treatment area.
- •·Patients with substantial history of environmental exposure to tainted rapeseed oil, vinyl chloride, L- tryptophan, bleomycin, trichoroethylene, or silica.
- •·PUVA therapy within 1 month of study drug initiation.
- •·Concurrent interventional therapy that might independently influence outcome of trial, such as D-penicillamine, cyclosporine, interferon-g or photopheresis.
- •·Topical corticosteroids treatment affecting the selected area.
- •·Cosmetics over the treatment area.
- •·Pregnant or breast-feeding women.
- •·Reasonable expectation that the subject will not be able to satisfactorily complete the study:
- •oHistory of or current psychiatric illness that would interfere with the subject’s ability to comply with protocol requirements or give informed consent.
- •oHistory of alcohol or drug abuse that would interfere with the subject’s ability to comply with protocol requirements.
- •oReceipt of any investigational drug within three months of screening visit.
- •oDocumented noncompliance.
研究者
相似试验
进行中（未招募）
不适用
Phase II, multicenter, randomized, double-blind, intraindividually placebo controlled clinical trial, to evaluate efficacy and safety of P144 topical administration for skin fibrosis in patients with systemic sclerosis. - NDSkin Fibrosis in patients with systemic sclerosisMedDRA version: 12.0Level: LLTClassification code 10039710Term: SclerodermaEUCTR2007-002015-38-ITISDIN S.A.98
进行中（未招募）
不适用
Safety and efficacy study of TRO40303 for reduction of reperfusion injury in patients undergoing Percutaneous Coronary Intervention for acute myocardial infarctioEUCTR2010-024616-33-SETROPHOS SA
进行中（未招募）
1 期
Safety and efficacy study of TRO40303 for reduction of reperfusion injury in patients undergoing Percutaneous Coronary Intervention for acute myocardial infarctioTreatment for cardiac reperfusion injury in patients undergoing PCI( Percutaneous coronary intervention) to treat an AMI (Acute Myocardial Infarction) and to assess safety as well as the ability of TRO40303 to reduce infarct size using biomarkers and MRI (Magnetic Resonance Imaging)MedDRA version: 14.1Level: LLTClassification code 10000930Term: Acute myocardial infarction, unspecified site, initial episode of careSystem Organ Class: 10007541 - Cardiac disordersEUCTR2010-024616-33-DKTROPHOS SA180
进行中（未招募）
不适用
A study to examine the effectiveness and safety of a new drug for involuntary muscle movements in patients with Parkinson’s diseaseParkinson’s disease levodopa induced dyskinesia (PD-LID)MedDRA version: 18.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-000373-13-DEAmarantus BioScience Holdings, Inc.60
进行中（未招募）
不适用
Phase IIa, multicenter, randomised, double-blind, placebo controlled study of the efficacy and safety of RO0506997, an a4 integrin antagonist, in combination with methotrexate, versus methotrexate alone, in patients with mild/moderate active rheumatoid arthritis (RA) who have had a partial response to a stable dose of methotrexate.EUCTR2004-004022-27-ESF.Hoffmann - La Roche Ltd160